Literature DB >> 23389605

Apoptosis therapy: driving cancers down the road to ruin.

Douglas R Green, Henning Walczak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23389605     DOI： 10.1038/nm.3076

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

1.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

Authors:  Mark F van Delft; Andrew H Wei; Kylie D Mason; Cassandra J Vandenberg; Lin Chen; Peter E Czabotar; Simon N Willis; Clare L Scott; Catherine L Day; Suzanne Cory; Jerry M Adams; Andrew W Roberts; David C S Huang
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

2.  Programmed anuclear cell death delimits platelet life span.

Authors:  Kylie D Mason; Marina R Carpinelli; Jamie I Fletcher; Janelle E Collinge; Adrienne A Hilton; Sarah Ellis; Priscilla N Kelly; Paul G Ekert; Donald Metcalf; Andrew W Roberts; David C S Huang; Benjamin T Kile
Journal:  Cell       Date:  2007-03-23       Impact factor: 41.582

3.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors:  Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

4.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

5.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Authors:  Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg
Journal:  Nature       Date:  2005-05-15       Impact factor: 49.962

6.  Direct and selective small-molecule activation of proapoptotic BAX.

Authors:  Evripidis Gavathiotis; Denis E Reyna; Joseph A Bellairs; Elizaveta S Leshchiner; Loren D Walensky
Journal:  Nat Chem Biol       Date:  2012-05-27       Impact factor: 15.040

Review 7.  The BCL-2 family reunion.

Authors:  Jerry E Chipuk; Tudor Moldoveanu; Fabien Llambi; Melissa J Parsons; Douglas R Green
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

8.  Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

Authors:  Thanh-Trang Vo; Jeremy Ryan; Ruben Carrasco; Donna Neuberg; Derrick J Rossi; Richard M Stone; Daniel J Deangelo; Mark G Frattini; Anthony Letai
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

9.  The landscape of somatic copy-number alteration across human cancers.

Authors:  Rameen Beroukhim; Craig H Mermel; Dale Porter; Guo Wei; Soumya Raychaudhuri; Jerry Donovan; Jordi Barretina; Jesse S Boehm; Jennifer Dobson; Mitsuyoshi Urashima; Kevin T Mc Henry; Reid M Pinchback; Azra H Ligon; Yoon-Jae Cho; Leila Haery; Heidi Greulich; Michael Reich; Wendy Winckler; Michael S Lawrence; Barbara A Weir; Kumiko E Tanaka; Derek Y Chiang; Adam J Bass; Alice Loo; Carter Hoffman; John Prensner; Ted Liefeld; Qing Gao; Derek Yecies; Sabina Signoretti; Elizabeth Maher; Frederic J Kaye; Hidefumi Sasaki; Joel E Tepper; Jonathan A Fletcher; Josep Tabernero; José Baselga; Ming-Sound Tsao; Francesca Demichelis; Mark A Rubin; Pasi A Janne; Mark J Daly; Carmelo Nucera; Ross L Levine; Benjamin L Ebert; Stacey Gabriel; Anil K Rustgi; Cristina R Antonescu; Marc Ladanyi; Anthony Letai; Levi A Garraway; Massimo Loda; David G Beer; Lawrence D True; Aikou Okamoto; Scott L Pomeroy; Samuel Singer; Todd R Golub; Eric S Lander; Gad Getz; William R Sellers; Matthew Meyerson
Journal:  Nature       Date:  2010-02-18       Impact factor: 49.962
  9 in total
  23 in total

Review 1.  Novel agents in follicular lymphoma: choosing the best target.

Authors:  Laurie H Sehn
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax.

Authors:  Karina J Matissek; Abood Okal; Mohanad Mossalam; Carol S Lim
Journal:  Pharm Res       Date:  2014-03-15       Impact factor: 4.200

3.  Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.

Authors:  S L Khaw; D Mérino; M A Anderson; S P Glaser; P Bouillet; A W Roberts; D C S Huang
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

Review 4.  Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies.

Authors:  Shaji Kumar
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.

Authors:  Maja Sochalska; Selma Tuzlak; Alexander Egle; Andreas Villunger
Journal:  FEBS J       Date:  2015-01-23       Impact factor: 5.542

6.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

7.  Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient.

Authors:  Sarolta Bojtine Kovacs; Jingting Luan; Sandra Maria Dold; Andreas Weis; Milena Pantic; Justus Duyster; Ralph Wäsch; Monika Engelhardt
Journal:  Haematologica       Date:  2019-08-29       Impact factor: 9.941

8.  Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer.

Authors:  Danchen Wu; Asish Dasgupta; Austin D Read; Rachel E T Bentley; Mehras Motamed; Kuang-Hueih Chen; Ruaa Al-Qazazi; Jeffrey D Mewburn; Kimberly J Dunham-Snary; Elahe Alizadeh; Lian Tian; Stephen L Archer
Journal:  Free Radic Biol Med       Date:  2021-01-12       Impact factor: 8.101

9.  Caspase Activation and Aberrant Cell Growth in a p53(+/+) Cell Line from a Li-Fraumeni Syndrome Family.

Authors:  Zaki A Sherif
Journal:  Genet Res Int       Date:  2015-03-18

Review 10.  Review of Venetoclax in CLL, AML and Multiple Myeloma.

Authors:  Masa Lasica; Mary Ann Anderson
Journal:  J Pers Med       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.